27-Feb-2025 3:05 PM CST - Business Wire Natera Reports Fourth Quarter and Full Year 2024 Financial Results Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Recent Financial Highlights Generated total revenues of $476.1 million in the fourth quarter of 2024, compared to $311.1 million in the fourth quarter of 2023, an increase of 53.0%. Product revenues grew 53.9% over the same period. Generated a gross margin of 62.9% in the fourth quart
18-Feb-2025 8:00 AM CST - Business Wire Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Nateras Fourth Quarter & Full Year 2024 Financial Results Date: February 27, 2025 Time: 1:30 p.m.
15-Jan-2025 6:00 AM CST - Business Wire Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, will provide an update to the investment community, today, at the 43rd annual J.P. Morgan Healthcare Conference. In addition to its previously announced preliminary financial results for the fourth quarter and year ended Dec. 31, 2024, the Company will also present details on its innovation roadmap for oncology. Building on our strong preliminary financial results in 2024, we are poised for a
12-Jan-2025 6:20 PM CST - Business Wire Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today released preliminary unaudited results for the fourth quarter and full year ended December 31, 2024. The Company expects the following: Total revenues of approximately $472 million in the fourth quarter of 2024 compared to $311 million in the fourth quarter of 2023, an increase of approximately 52%. Total revenues of approximately $1.7 billion in the full year 2024 compared t
12-Nov-2024 3:05 PM CST - Business Wire Natera Reports Third Quarter 2024 Financial Results Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the third quarter ended September 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $439.8 million in the third quarter of 2024, compared to $268.3 million in the third quarter of 2023, a record increase of 63.9%. Product revenues grew 64.4% over the same period. Generated a gross margin of 61.8% in the third qu
8-Nov-2024 8:00 AM CST - Business Wire Natera to Participate in Upcoming Investor Conferences Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of its leadership team will present at the following investor conferences in November and December. The UBS Global Healthcare Conference on Thursday, Nov. 14 at 11:00 am ET | 8:00 am PT in Rancho Palos Verdes, CA. The Wolfe Research Healthcare Conference on Tuesday, Nov. 19 at 11:00 am ET | 8:00 am PT in New York, NY. The 36th Annual Piper Sandler Healt
1-Nov-2024 8:00 AM CST - Business Wire Natera to Report its Third Quarter 2024 Results on November 12, 2024 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its third quarter ended Sept. 30, 2024, after the market closes on Nov. 12, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Nateras Third Quarter 2024 Financial Results Date: Tuesday, Nov. 1
Latest NTRA Trades by Congress Members
20-NOV-2024 - Josh Gottheimer, NJ (District 5) purchased between $1,001 and $15,000.
27-Feb-2025 3:05 PM CST - Business Wire Natera Reports Fourth Quarter and Full Year 2024 Financial Results Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Recent Financial Highlights Generated total revenues of $476.1 million in the fourth quarter of 2024, compared to $311.1 million in the fourth quarter of 2023, an increase of 53.0%. Product revenues grew 53.9% over the same period. Generated a gross margin of 62.9% in the fourth quart
18-Feb-2025 8:00 AM CST - Business Wire Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Nateras Fourth Quarter & Full Year 2024 Financial Results Date: February 27, 2025 Time: 1:30 p.m.
15-Jan-2025 6:00 AM CST - Business Wire Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, will provide an update to the investment community, today, at the 43rd annual J.P. Morgan Healthcare Conference. In addition to its previously announced preliminary financial results for the fourth quarter and year ended Dec. 31, 2024, the Company will also present details on its innovation roadmap for oncology. Building on our strong preliminary financial results in 2024, we are poised for a
12-Jan-2025 6:20 PM CST - Business Wire Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today released preliminary unaudited results for the fourth quarter and full year ended December 31, 2024. The Company expects the following: Total revenues of approximately $472 million in the fourth quarter of 2024 compared to $311 million in the fourth quarter of 2023, an increase of approximately 52%. Total revenues of approximately $1.7 billion in the full year 2024 compared t
12-Nov-2024 3:05 PM CST - Business Wire Natera Reports Third Quarter 2024 Financial Results Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the third quarter ended September 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $439.8 million in the third quarter of 2024, compared to $268.3 million in the third quarter of 2023, a record increase of 63.9%. Product revenues grew 64.4% over the same period. Generated a gross margin of 61.8% in the third qu
8-Nov-2024 8:00 AM CST - Business Wire Natera to Participate in Upcoming Investor Conferences Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of its leadership team will present at the following investor conferences in November and December. The UBS Global Healthcare Conference on Thursday, Nov. 14 at 11:00 am ET | 8:00 am PT in Rancho Palos Verdes, CA. The Wolfe Research Healthcare Conference on Tuesday, Nov. 19 at 11:00 am ET | 8:00 am PT in New York, NY. The 36th Annual Piper Sandler Healt
1-Nov-2024 8:00 AM CST - Business Wire Natera to Report its Third Quarter 2024 Results on November 12, 2024 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its third quarter ended Sept. 30, 2024, after the market closes on Nov. 12, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Nateras Third Quarter 2024 Financial Results Date: Tuesday, Nov. 1
